LLY
Eli Lilly
$1.08Tn
1,148.74
-0.93%
+55.69%
Eli Lilly discovers, develops, manufactures, and markets branded prescription drugs across therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience. Its revenue is primarily generated from the sale of branded pharmaceutical products like insulin analogs and GLP-1 receptor agonists.
JNJ
Johnson & Johnson
$663.08Bn
275.15
-1.19%
+54.58%
The company's Innovative Medicine segment generates significant revenue from branded prescription pharmaceuticals such as STELARA, TREMFYA, and XARELTO. These products are sold to retailers, wholesalers, and hospitals for the treatment of oncology, immunology, and cardiovascular diseases.
ABBV
AbbVie
$453.04Bn
256.37
-1.48%
+20.36%
AbbVie is a diversified pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as Vraylar, Ubrelvy, Qulipta, and Mavyret.
MRK
Merck
$370.87Bn
150.32
-1.33%
+78.85%
Merck's primary revenue driver is the sale of branded prescription pharmaceuticals and vaccines for human health, with 2025 pharmaceutical sales totaling $58,142 million. Key branded products cited include Keytruda, Gardasil, and Januvia.
NVS
Novartis Ag
$305.29Bn
159.99
-1.89%
+24.58%
Novartis is an innovative medicines company that researches, develops, manufactures, and markets branded prescription pharmaceuticals across therapeutic areas such as cardiovascular, renal, metabolic diseases, immunology, neuroscience, and oncology. Its primary revenue is generated from the sale of these pharmaceutical products to wholesalers, health systems, and government agencies.
NVO
Novo Nordisk A S
$223.78Bn
46.62
-1.89%
-17.84%
Novo Nordisk discovers, develops, and markets branded prescription pharmaceuticals, specifically GLP-1 receptor agonists like Ozempic and Wegovy for obesity and diabetes. Its revenue is primarily generated from the sale of these branded pharmaceutical products.
GILD
2nd
Gilead Sciences
$187.38Bn
150.99
-0.15%
+33.63%
Gilead develops and markets branded prescription small-molecule antiviral drugs for HIV and hepatitis, such as Biktarvy, Descovy, and Epclusa.
PFE
Pfizer
$162.10Bn
28.44
-1.32%
+15.89%
Pfizer is a global biopharmaceutical company that discovers, develops, and markets a vast portfolio of branded prescription drugs and vaccines, including Eliquis, Prevnar, and Paxlovid. Its primary revenue is generated from the sale of these branded pharmaceutical products to hospitals, patients, and healthcare providers.
VRTX
2nd
Vertex Pharmaceuticals
$138.36Bn
546.12
-2.12%
+37.69%
Vertex develops and manufactures branded small-molecule prescription drugs, such as its cystic fibrosis modulators (e.g., TRIKAFTA) and the oral pain inhibitor JOURNAVX.
BMY
Bristol Myers Squibb
$136.51Bn
66.83
-1.85%
+40.69%
Bristol Myers Squibb is a large pharmaceutical firm that discovers, develops, and markets a wide portfolio of branded prescription medicines such as Eliquis, Sprycel, and Abraxane. Its revenue is primarily generated from the sale of these innovative branded pharmaceuticals across multiple therapeutic areas.
SNY
Sanofi
$53.95Bn
44.24
-0.20%
-11.32%
Sanofi is a global pharmaceutical company that discovers, develops, and markets branded prescription drugs across multiple therapeutic areas. Its revenue is primarily derived from the sale of branded medicines such as Dupixent for immunology and Sarclisa for oncology.
RVMD
Revolution Medicines
$45.00Bn
210.02
-0.40%
+428.09%
Revolution Medicines is a clinical-stage company developing small-molecule RAS(ON) inhibitors for cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. Its core business is the discovery and development of branded prescription pharmaceuticals based on its proprietary tri complex technology platform.
TEVA
2nd
Teva Pharmaceutical Industries
$42.34Bn
36.33
-0.76%
+96.59%
The company develops and sells patented innovative medicines such as AUSTEDO, AJOVY, UZEDY, and COPAXONE for neurological and oncological indications.
ONC
BeOne Medicines
$40.49Bn
358.26
-1.22%
+6.54%
BeOne Medicines discovers, develops, and markets branded prescription drugs for oncology, specifically hematology and solid tumors. Its primary revenue is derived from the sales of branded medicines such as BRUKINSA and TEVIMBRA.
ALC
2nd
Alcon
$34.36Bn
70.50
-2.18%
-10.44%
Alcon develops and markets branded prescription pharmaceuticals for ocular health, including Rocklatan and Rhopressa for the treatment of glaucoma.
GEHC
2nd
GE HealthCare Technologies
$31.10Bn
68.86
-1.23%
-4.86%
The Pharmaceutical Diagnostics segment develops and sells branded prescription pharmaceuticals, specifically contrast media and radiopharmaceutical imaging agents used in radiology and nuclear medicine.
INSM
2nd
Insmed
$27.57Bn
126.29
-0.31%
-11.99%
Insmed also develops small-molecule branded prescription drugs, such as brensocatib, a small molecule inhibitor of dipeptidyl peptidase 1 for the treatment of hidradenitis suppurativa.
INCY
Incyte
$25.47Bn
126.75
-0.98%
+45.76%
Incyte is a biopharmaceutical company that discovers, develops, and markets branded prescription drugs such as JAKAFI, ICLUSIG, and OPZELURA. Its revenue is primarily derived from the sale of these branded pharmaceutical products to specialty pharmacies, hospital pharmacies, and wholesalers.
ROIV
2nd
Roivant Sciences
$25.24Bn
34.93
+1.51%
+177.44%
The company also develops branded small-molecule prescription drugs, such as brepocitinib (a TYK2/JAK1 inhibitor) developed through its Priovant subsidiary.
UTHR
United Therapeutics
$20.81Bn
487.61
-0.54%
+24.57%
The company's primary revenue is derived from the sale of branded prescription pharmaceuticals for pulmonary hypertension and oncology, specifically Tyvaso DPI, Remodulin, Orenitram, and Unituxin.
VTRS
2nd
Viatris
$19.39Bn
16.88
-0.35%
+60.00%
The company maintains a significant portfolio of branded products, including those protected by patent or marketed as branded generics, which contribute a significant portion of its sales.
JAZZ
Jazz Pharmaceuticals
$16.02Bn
246.81
-0.31%
+92.79%
Jazz Pharmaceuticals develops and markets branded prescription drugs for rare diseases, including Xywav for sleep disorders, Epidiolex for epilepsies, and Zepzelca for oncology. Its revenue is primarily generated through net product sales of these specialized, branded medications.
NBIX
Neurocrine Biosciences
$15.81Bn
155.64
-1.71%
+14.35%
Neurocrine Biosciences develops and markets branded prescription drugs, with the vast majority of its revenue coming from the sale of INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia. These are branded small-molecule pharmaceuticals sold through specialty pharmacies and wholesale distributors.
EXEL
Exelixis
$14.69Bn
59.01
-0.20%
+59.66%
Exelixis focuses on the discovery, development, and commercialization of branded prescription oncology medicines, specifically small molecule tyrosine kinase inhibitors. Its primary revenue is generated from the net product sales of branded drugs such as CABOMETYX and COMETRIQ.
BWXT
2nd
BWX Technologies
$14.44Bn
157.56
-1.70%
-2.11%
The company produces and sells radiopharmaceuticals and medical radioisotopes to hospitals and pharmaceutical firms for diagnostic and therapeutic applications.
CORT
Corcept Therapeutics
$12.07Bn
111.62
-1.05%
+56.46%
Corcept Therapeutics discovers, develops, and markets branded prescription drugs, specifically its lead product Korlym for the treatment of hypercortisolism. Its revenue is generated from the sale of these branded pharmaceuticals to physicians and healthcare providers.
AXSM
Axsome Therapeutics
$10.81Bn
206.68
-0.80%
+66.13%
Axsome is a fully integrated biopharmaceutical company that manufactures and markets branded prescription drugs, including AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for migraine. Its core revenue stream comes from the sale of these branded pharmaceutical products in the United States.
GKOS
2nd
Glaukos
$10.46Bn
177.67
-1.52%
+88.07%
The company develops and commercializes branded pharmaceutical products, such as the iDose TR intracameral pharmaceutical implant and iLink therapies for corneal crosslinking. These branded prescription therapies represent a material portion of the company's revenue and product pipeline.
GPCR
Structure Therapeutics
$10.11Bn
47.34
+0.00%
+140.18%
Structure Therapeutics is a biopharmaceutical company focused on discovering and developing oral small molecule therapeutics, such as aleniglipron (a GLP1R agonist) and amylin receptor agonists. Because its pipeline consists of small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification.
CYTK
Cytokinetics
$10.11Bn
72.72
-1.66%
+45.47%
Cytokinetics develops and markets branded prescription drugs, specifically the oral small molecule inhibitor MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy. Its revenue is generated from the sales of these branded pharmaceuticals and associated licensing milestones.
PRAX
2nd
Praxis Precision Medicines
$9.82Bn
351.81
-0.94%
+655.77%
The company also develops small molecule therapies through its Cerebrum platform, including candidates like ulixacaltamide and relutrigine for which it has submitted New Drug Applications (NDAs).
NUVL
Nuvalent
$9.75Bn
123.96
+0.00%
+50.33%
Nuvalent is a biopharmaceutical company developing small molecule inhibitors, such as zidesamtinib (NVL-520) and neladalkib (NVL-655), which are branded prescription drug candidates. Its core business is the discovery and development of small-molecule pharmaceuticals for oncology.
KYMR
Kymera Therapeutics
$9.72Bn
117.39
+0.09%
+171.11%
Kymera Therapeutics develops oral small molecule medicines, such as those targeting STAT6, IRF5, IRAK4, and CDK2, which are branded prescription pharmaceuticals. The company's core business is the discovery and development of these small-molecule drugs to treat immune inflammatory diseases and oncology.
CRNX
Crinetics Pharmaceuticals
$8.99Bn
84.95
+0.00%
+155.11%
Crinetics Pharmaceuticals discovers, develops, and markets branded prescription drugs, specifically small-molecule oral agents like PALSONIFY (paltusotine) for acromegaly. Its revenue is generated from the sales of these branded pharmaceutical products and milestone payments from licensing agreements.
ALKS
Alkermes
$7.72Bn
46.10
-1.66%
+53.67%
Alkermes develops and markets branded prescription drugs for neuroscience disorders, including ARISTADA, LYBALVI, VIVITROL, and LUMRYZ. Its primary revenue is generated through the direct sales of these proprietary branded pharmaceuticals.
BLTE
Belite Bio
$7.62Bn
193.61
+13.16%
+204.85%
Belite Bio is a clinical-stage company developing branded prescription drugs, specifically oral small molecules like tinlarebant (LBS 008) and LBS 009. These candidates target therapeutic areas such as Stargardt disease, geographic atrophy, and metabolic disorders like type 2 diabetes.
BLRX
2nd
BioLineRx
$6.97Bn
2.67
-0.74%
-26.45%
The company also develops small-molecule drugs, specifically GLIX1, which is described as a first-in-class oral small molecule used to induce DNA damage in glioblastoma tumors.
BLCO
2nd
Bausch & Lomb
$6.45Bn
18.07
-0.44%
+23.85%
The company develops and markets branded prescription eye medications for conditions like glaucoma and dry eye, specifically citing products such as MIEBO, XIIDRA, and Vyzulta.
TVTX
Travere Therapeutics
$6.15Bn
65.28
-1.89%
+208.65%
Travere Therapeutics develops and markets branded prescription drugs for rare kidney and metabolic diseases, such as FILSPARI (sparsentan) for IgAN and Thiola for cystinuria. Its revenue is primarily generated from the sales of these branded pharmaceutical products.
LQDA
Liquidia
$6.12Bn
68.66
+0.04%
+134.98%
Liquidia develops and markets branded prescription drugs for respiratory and vascular conditions, specifically its lead commercial product YUTREPIA. Revenue is primarily derived from the sale of this branded pharmaceutical to patients and healthcare providers.
AMRN
Amarin Corp Plc\Uk
$5.73Bn
13.63
-0.58%
-9.37%
Amarin is a pharmaceutical company that develops and markets branded prescription drugs, specifically its flagship product VASCEPA (icosapent ethyl). Its revenue is primarily generated from the sale of this branded pharmaceutical to wholesalers and through licensing agreements with commercial collaborators.
AMRX
2nd
Amneal Pharmaceuticals
$5.57Bn
17.44
-2.41%
+82.81%
The Specialty segment generates revenue from branded prescription pharmaceuticals for central nervous system and endocrine disorders, specifically citing products like CREXONT®, RYTARY®, UNITHROID®, and Brekiya®.
ERAS
2nd
Erasca
$5.06Bn
16.19
-0.43%
+1,032.17%
In addition to biologics, the company develops small molecule therapeutics, including the pan RAS molecular glue (ERAS 0015) and the pan KRAS inhibitor (ERAS 4001), which fall under branded pharmaceutical development.
ACAD
Acadia Pharmaceuticals
$4.82Bn
28.02
+0.57%
+8.94%
Acadia Pharmaceuticals develops and markets branded prescription drugs, specifically NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. Its revenue is derived almost exclusively from the net product sales of these branded pharmaceuticals.
EWTX
Edgewise Therapeutics
$4.64Bn
43.07
+2.67%
+194.60%
Edgewise Therapeutics focuses on discovering and developing small molecule therapies, such as sevasemten and EDG-7500, for muscle diseases. Because its pipeline consists of small-molecule drug candidates rather than biologics, it fits the Pharmaceuticals classification.
ELVN
Enliven Therapeutics
$4.35Bn
59.32
-0.55%
+196.45%
Enliven Therapeutics is a clinical-stage company focused on the discovery and development of small molecule therapeutics, such as ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 inhibition. These are branded prescription drug candidates rather than biologics, placing the company in the Pharmaceuticals category.
DFTX
Definium Therapeutics
$4.22Bn
38.09
+0.24%
+320.42%
Definium Therapeutics is developing branded prescription drugs for brain health disorders, specifically DT120 (lysergide d tartrate) and DT402 (R enantiomer of MDMA). These are small-molecule pharmaceutical compounds targeting generalized anxiety disorder, major depressive disorder, and autism spectrum disorder.
INDV
Indivior Pharmaceuticals
$4.12Bn
34.94
+0.32%
+41.63%
Indivior develops and markets branded prescription pharmaceuticals, specifically SUBLOCADE and SUBOXONE Film, for the treatment of opioid use disorder. Its revenue is derived from the sale of these branded medications to healthcare providers, pharmacies, and distributors.
MANE
Veradermics
$4.11Bn
98.31
+0.57%
—
Veradermics is developing VDPHL01, an oral extended-release formulation of minoxidil, which is a branded prescription drug for pattern hair loss. The company intends to generate revenue from prescriptions written by dermatologists and primary care physicians.
TARS
Tarsus Pharmaceuticals
$3.93Bn
90.78
+9.10%
+58.07%
Tarsus Pharmaceuticals develops and markets branded prescription drugs, specifically XDEMVY lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company generates the majority of its revenue from the sales of this branded pharmaceutical product to eye care professionals and patients.
CPRX
Catalyst Pharmaceuticals
$3.85Bn
31.49
+0.00%
+49.88%
Catalyst Pharmaceuticals is a commercial-stage company that markets branded prescription drugs for rare diseases, specifically FIRDAPSE, AGAMREE, and FYCOMPA. Its revenue is primarily derived from the sale of these branded pharmaceutical products to patients and physicians.
RCUS
2nd
Arcus Biosciences
$3.77Bn
29.65
-1.59%
+156.49%
In addition to antibodies, the company develops small molecule therapies, such as the HIF-2α inhibitor casdatifan and the CD73 inhibitor vemliclustat, which fall under branded pharmaceutical development.
OGN
Organon
$3.62Bn
13.78
+0.00%
+40.18%
Organon's primary revenue comes from the sale of branded prescription pharmaceuticals, specifically its Women's Health segment featuring products like Nexplanon and NuvaRing. The company markets these branded medicines across therapeutic areas including contraception, fertility, and cardiovascular health.
DNLI
2nd
Denali Therapeutics
$3.56Bn
22.28
-2.28%
+45.53%
The company also pursues small molecule programs, such as LRRK2 inhibitors for Parkinson's disease, which falls under the development of branded prescription pharmaceuticals.
IMNM
2nd
Immunome
$3.03Bn
26.76
-1.47%
+173.06%
The company also develops small-molecule inhibitors, such as the oral gamma secretase inhibitor varegacestat, which falls under the development of branded prescription pharmaceuticals.
NAMS
NewAmsterdam Pharma
$2.99Bn
25.40
-1.74%
+2.09%
NewAmsterdam Pharma is developing obicetrapib, a branded prescription drug for cardiometabolic diseases and Alzheimer's. The company plans to commercialize this small-molecule CETP inhibitor independently in the US and via licensing in Europe, generating revenue from direct sales, milestone payments, and royalties.
ZLAB
2nd
Zai Lab
$2.94Bn
26.23
-2.85%
-12.57%
The company also commercializes branded prescription small-molecule pharmaceuticals, such as QINLOCK for gastrointestinal stromal tumors and AUGTYRO for non-small cell lung cancer.
SLS
2nd
SELLAS Life Sciences
$2.80Bn
13.86
+1.17%
+678.65%
In addition to its peptide immunotherapy, the company is developing SLS009, which is described as a highly selective small molecule inhibitor of cyclin dependent kinase 9.
NRIX
2nd
Nurix Therapeutics
$2.71Bn
26.14
+3.24%
+186.62%
The company develops small molecule degrader drugs, such as bexobrutideg and zelebrudomide, which are branded prescription drug candidates for the treatment of cancer and inflammatory diseases.
TAK
Takeda Pharmaceutical
$2.67Bn
18.47
-1.23%
+21.91%
Takeda is a global pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as ENTYVIO for inflammatory bowel disease and VYVANSE for ADHD.
CURLF
2nd
Curaleaf Holdings
$2.61Bn
9.86
+3.46%
+19.95%
Curaleaf operates pharma-grade manufacturing facilities in Europe (Germany, Spain, Canada, Portugal, and the UK) that produce cannabinoid-based pharmaceutical products for medical use.
BCRX
2nd
Biocryst Pharmaceuticals
$2.54Bn
9.96
-1.29%
+20.14%
The company also develops and markets branded small-molecule prescription drugs, most notably ORLADEYO (berotralstat), an oral therapy for the prevention of hereditary angioedema attacks.
SUPN
Supernus Pharmaceuticals
$2.53Bn
43.53
-1.00%
-3.12%
Supernus Pharmaceuticals develops and markets branded prescription drugs for CNS diseases, such as Qelbree for ADHD and ZURZUVAE for postpartum depression. Its revenue is primarily generated from the sale of these proprietary branded pharmaceuticals to wholesalers and specialty pharmacies.
MLYS
Mineralys Therapeutics
$2.49Bn
28.21
-0.21%
-14.82%
Mineralys Therapeutics is developing lorundrostat, an oral aldosterone synthase inhibitor, which is a branded prescription drug candidate for hypertension and cardiorenal conditions. The company's core business is the discovery and development of this small-molecule pharmaceutical to treat diseases driven by dysregulated aldosterone.
TRVI
Trevi Therapeutics
$2.46Bn
17.26
+1.17%
+141.40%
Trevi Therapeutics is a clinical-stage company developing Haduvio (oral nalbuphine ER), which is a small-molecule branded prescription drug candidate for chronic cough. The company's focus is on the discovery and development of this branded pharmaceutical therapy for patients with idiopathic pulmonary fibrosis and refractory cough.
HRMY
Harmony Biosciences Holdings
$2.46Bn
42.25
+0.93%
+12.58%
Harmony Biosciences discovers, develops, and markets branded prescription drugs for rare neurological diseases, with the vast majority of its revenue coming from the sale of its branded product WAKIX (pitolisant). The company's business model is centered on branded pharmaceutical sales to specialty pharmacies and distributors.
BHC
2nd
Bausch Health Companies
$2.45Bn
6.56
-2.96%
-10.75%
The company develops and markets branded prescription pharmaceuticals, specifically citing the Xifaxan product line within its Salix segment.
BHVN
2nd
Biohaven
$2.37Bn
15.69
-1.07%
-2.36%
The company also develops small-molecule pharmacological approaches, such as the Kv7 ion channel modulation platform for opakalim (BHV-7000) used in epilepsy and depressive disorders.
NUVB
Nuvation Bio
$2.36Bn
6.81
+0.59%
+99.12%
Nuvation Bio develops and markets branded prescription oncology drugs, specifically the FDA-approved IBTROZI for ROS1 positive non small cell lung cancer. Its revenue is generated through direct product sales in the US and licensing/royalties from partners like Eisai and Nippon Kayaku.
PVLA
Palvella Therapeutics
$2.26Bn
157.24
+1.14%
+193.85%
Palvella Therapeutics is a biopharmaceutical company developing branded prescription topical therapies, such as QTORIN rapamycin and QTORIN pitavastatin, for rare skin diseases. These are small-molecule active ingredients (rapamycin and pitavastatin) formulated into gels, fitting the profile of branded pharmaceutical development.
AUPH
Aurinia Pharmaceuticals
$2.14Bn
16.08
-0.25%
+34.00%
Aurinia Pharmaceuticals develops and markets branded prescription drugs, specifically its flagship oral therapy LUPKYNIS for lupus nephritis. The company generates the majority of its revenue from the direct sale of this branded pharmaceutical product in the U.S. and through royalties and supply agreements internationally.
FMS
2nd
Fresenius Medical Care AG
$2.11Bn
22.66
+0.89%
-6.98%
The company develops and markets renal pharmaceuticals, specifically mentioning erythropoietin stimulating agents, iron sucrose, and phosphate binders.
ZBIO
2nd
Zenas BioPharma
$2.08Bn
32.88
-0.12%
+91.83%
In addition to its biologics, the company is developing orelabrutinib, which is described as an oral BTK inhibitor, representing a small-molecule pharmaceutical development program.
ANIP
2nd
Ani Pharmaceuticals
$1.70Bn
71.23
-1.06%
-25.80%
The company operates a 'Rare Disease and Brands' segment that commercializes branded prescription drugs such as Cortrophin Gel, ILUVIEN, and YUTIQ, as well as a portfolio including Atacand and Arimidex.
AAPG
2nd
Ascentage Pharma Group International
$1.66Bn
17.77
+2.36%
-56.98%
The company develops and markets branded prescription drugs, such as Olverembatinib and Lisaftoclax, which are sold to hospitals and pharmacies for the treatment of leukemia and other blood cancers.
ETON
Eton Pharmaceuticals
$1.65Bn
58.45
-2.42%
+227.08%
Eton Pharmaceuticals develops and markets branded prescription drugs for rare diseases, such as INCRELEX for insulin-like growth factor 1 deficiency and GALZIN for Wilson disease. Its revenue is derived from the sale of these branded pharmaceutical products to healthcare providers and patients.
INVA
Innoviva
$1.55Bn
21.33
-0.09%
+2.06%
Innoviva develops and commercializes a portfolio of branded prescription therapeutics for critical care and infectious diseases, including GIAPREZA, XACDURO, XERAVA, and ZEVTERA. It also earns significant revenue from branded respiratory products developed in collaboration with GSK.
RARE
2nd
Ultragenyx Pharmaceutical
$1.51Bn
15.30
+3.03%
-51.09%
In addition to biologics, the company's product modalities include small molecules, which are used to develop branded prescription drugs for rare indications.
AVBP
2nd
ArriVent BioPharma
$1.50Bn
30.95
-0.26%
+58.56%
The company is developing firmonertinib, a tyrosine kinase inhibitor (TKI), which is a small-molecule branded prescription drug candidate for non-small cell lung cancer.
XERS
Xeris Biopharma Holdings
$1.48Bn
8.53
-0.70%
+8.80%
Xeris Biopharma develops and markets branded prescription drugs such as Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. Its revenue is generated through the sale of these branded pharmaceutical products to patients via healthcare provider prescriptions.
HROW
Harrow
$1.44Bn
38.54
+0.73%
+3.21%
Harrow develops and markets a wide range of FDA-approved branded ophthalmic pharmaceuticals, such as IHEEZO, VEVYE, and VIGAMOX. Its primary revenue is generated from the sale of these branded prescription products for conditions like dry eye and glaucoma.
LBRX
Lb Pharmaceuticals
$1.42Bn
49.34
+3.83%
+185.20%
Lb Pharmaceuticals is developing LB 102, a branded prescription drug candidate for neuropsychiatric disorders like schizophrenia and bipolar depression. The company expects future revenue from the commercial sale of oral and long-acting injectable formulations of this branded pharmaceutical to healthcare providers and patients.
OMER
2nd
Omeros
$1.37Bn
18.95
-0.84%
+353.35%
In addition to biologics, the company develops small molecule therapeutics, such as the PDE7 inhibitor OMS527 and MASP 2/3 small molecule inhibitors, which fall under branded pharmaceutical development.
OPK
Opko Health
$1.22Bn
1.64
+1.86%
+18.84%
The company develops, manufactures, and markets branded prescription drugs such as the growth hormone NGENLA and the kidney disease treatment Rayaldee. It generates significant revenue from direct sales of these branded pharmaceuticals and royalty payments from partners like Pfizer.
CRVS
2nd
Corvus Pharmaceuticals
$1.21Bn
14.39
-1.77%
+156.05%
The company also develops small molecule inhibitors, such as the oral ITK inhibitor soquelitinib and the adenosine A2A receptor antagonist ciforadenant, which fall under branded pharmaceutical development.
KURA
Kura Oncology
$1.18Bn
13.25
+0.76%
+57.18%
Kura Oncology discovers, develops, and markets branded prescription small-molecule therapeutics, specifically the FDA-approved drug KOMZIFTI for the treatment of NPM1-mutated AML. Its revenue is derived from the commercial sale of this branded pharmaceutical product.
PCRX
Pacira BioSciences
$1.05Bn
26.35
-0.94%
-3.05%
The company's primary revenue is derived from branded prescription pharmaceuticals, specifically EXPAREL (a long-acting local analgesic) and ZILRETTA (an extended-release corticosteroid), which together account for the vast majority of its total revenue.
MNPR
2nd
Monopar Therapeutics
$1.00Bn
117.56
-0.84%
+224.66%
The company is developing ALXN1840, a small-molecule oral drug for the treatment of Wilson disease, which falls under the category of branded prescription pharmaceuticals.
LXRX
Lexicon Pharmaceuticals
$1.00Bn
2.24
-0.88%
+107.41%
Lexicon is a biopharmaceutical company that discovers, develops, and markets branded prescription drugs, specifically commercializing INPEFA for heart failure. Its revenue is derived from the sales of this branded pharmaceutical product and licensing agreements for other small-molecule drug candidates.
SGP
SpyGlass Pharma
$967.94Mn
28.94
-0.17%
—
SpyGlass Pharma is a biopharmaceutical company developing branded prescription drug delivery systems, specifically the BIM IOL System and BIM DRS, to treat glaucoma and ocular hypertension using the drug bimatoprost. Its revenue model is based on the sale of these branded pharmaceutical products and associated reimbursement for the physician-administered drug component.
DSGN
Design Therapeutics
$947.46Mn
15.14
+0.73%
+147.79%
Design Therapeutics is a clinical-stage company developing GeneTAC molecules, which it explicitly describes as a 'novel class of small molecule' therapeutics. Because its core platform focuses on small-molecule drug discovery for branded prescription use (targeting diseases like Friedreich ataxia and Huntington's disease) rather than biologics, it fits the Pharmaceuticals category.
OLMA
Olema Pharmaceuticals
$940.11Mn
10.75
+0.19%
+70.91%
Olema Pharmaceuticals is a clinical-stage company developing novel small molecule therapeutics, such as palazestrant and OP-3136, for breast cancer. Its business model focuses on the discovery, development, and eventual commercialization of branded prescription drugs.
IVA
Inventiva
$923.67Mn
4.78
-1.24%
-17.16%
Inventiva is a clinical-stage company developing lanifibranor, which is described as an oral small molecule therapy. Because the lead candidate is a small-molecule drug rather than a biologic, it fits the Pharmaceuticals category for branded prescription drug development.
ACRS
2nd
Aclaris Therapeutics
$862.72Mn
6.17
+3.70%
+199.51%
In addition to biologics, the company develops covalent small molecule inhibitors targeting pathways such as ITK, which falls under the discovery and development of branded prescription pharmaceuticals.
COLL
Collegium Pharmaceutical
$764.69Mn
23.53
-0.72%
-40.57%
Collegium develops and markets branded prescription drugs, including Jornay PM for ADHD and Xtampza ER for pain management. Its revenue is generated from the sale of these branded pharmaceutical products to wholesale distributors.
PHAT
Phathom Pharmaceuticals
$760.67Mn
9.50
+4.97%
-20.83%
Phathom Pharmaceuticals develops and markets branded prescription drugs, specifically VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK for gastrointestinal diseases. Its revenue is generated solely from the sale of these branded pharmaceutical products in the United States.
VSTM
Verastem
$741.95Mn
8.20
+2.76%
-13.68%
Verastem discovers, develops, and markets branded prescription drugs, specifically the AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Its revenue is derived principally from the sales of this branded pharmaceutical product in the United States.
ZVRA
Zevra Therapeutics
$735.84Mn
12.40
-1.12%
+38.86%
Zevra Therapeutics develops and markets branded prescription drugs for rare diseases, specifically MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders. Its revenue is derived from the sale of these branded pharmaceutical products through specialty pharmacy distribution channels.
GYRE
Gyre Therapeutics
$727.39Mn
6.86
+6.52%
-15.10%
Gyre Therapeutics is a commercial-stage company that develops and markets branded small-molecule prescription drugs. Its revenue is driven by the sale of branded therapies such as ETUARY® (pirfenidone), Etorel® (nintedanib), and Contiva® (avatrombopag).
AQST
Aquestive Therapeutics
$670.23Mn
5.34
-0.19%
+5.53%
Aquestive Therapeutics is a pharmaceutical company that develops and markets branded prescription drugs, such as Libervant for epilepsy rescue. Its business model focuses on creating alternative administration methods for complex molecules to replace standard of care therapies.
CRMD
CorMedix
$654.73Mn
8.43
-0.47%
-34.14%
CorMedix develops and markets branded prescription pharmaceuticals, most notably DefenCath, an FDA-approved antimicrobial catheter lock solution. The company also sells a portfolio of branded anti-infective agents such as REZZAYO and VABOMERE, and the cardiovascular product TOPROL XL.
NVCT
Nuvectis Pharma
$653.76Mn
24.49
+0.49%
+285.67%
Nuvectis Pharma is a clinical-stage company developing small molecule drug candidates, specifically NXP900, which is a targeted small molecule inhibitor of SRC and YES1 kinases. Because its lead candidates are small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification for branded prescription drug development.
OCS
2nd
Oculis Holding AG
$635.80Mn
12.17
+0.00%
-25.61%
The company is also developing OCS 01 (a dexamethasone formulation) and Privosegtor (a peptoid small molecule), which are branded small-molecule pharmaceutical candidates.
MPLT
MapLight Therapeutics
$625.67Mn
13.77
+4.79%
—
MapLight Therapeutics is a biopharmaceutical company developing branded prescription drug candidates for CNS disorders, such as ML-007C-MA for schizophrenia and Alzheimer's disease psychosis. Its pipeline consists of small-molecule agonists and antagonists, such as the M1/M4 muscarinic agonist and the GPR52 positive allosteric modulator ML-009.
EOLS
Evolus
$613.93Mn
9.30
+2.76%
+26.02%
Evolus develops and markets branded prescription products for aesthetic use, specifically Jeuveau (a botulinum toxin) and Evolysse (hyaluronic acid gels). These are branded pharmaceutical products sold to licensed aesthetic practitioners for the treatment of frown lines and wrinkles.
DCTH
2nd
Delcath Systems
$570.81Mn
16.48
+0.00%
+48.47%
The company markets the HEPZATO KIT, which is a drug/device combination involving the delivery of chemotherapy (melphalan) for the treatment of uveal melanoma liver metastases, and holds orphan drug designations for its therapies.
SPRY
ARS Pharmaceuticals
$558.84Mn
5.62
-0.88%
-47.43%
ARS Pharmaceuticals develops and markets neffy, a branded prescription intranasal epinephrine spray for the emergency treatment of anaphylaxis. Revenue is generated from the sale of this branded pharmaceutical product to wholesalers and pharmacies.
OVID
Ovid Therapeutics
$517.32Mn
2.80
+0.72%
+110.53%
Ovid Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule medicines, such as the GABA aminotransferase inhibitor OV329, to treat brain disorders. Its business model targets the development of branded prescription pharmaceuticals for indications including epilepsy, psychosis, and neuropsychiatric manifestations.
ANL
2nd
Adlai Nortye
$515.40Mn
15.01
+1.76%
+743.26%
In addition to biologics, the company develops branded small-molecule prescription drugs for oncology, such as the oral pan RAS(ON) inhibitor AN9025 and the oral PD-L1 inhibitor AN4005.
XFOR
X4 Pharmaceuticals
$510.43Mn
4.04
+0.00%
+10.99%
X4 Pharmaceuticals develops and markets branded prescription drugs, specifically the small-molecule oral antagonist XOLREMDI (mavorixafor) for the treatment of WHIM syndrome. Its revenue is derived from the sale of this branded pharmaceutical product and associated licensing and royalty payments.
EVMN
2nd
Evommune
$445.18Mn
12.27
+2.16%
—
The company is also developing EVO756, which is described as an oral small molecule antagonist, fitting the profile of a branded prescription pharmaceutical developer.
IKT
Inhibikase Therapeutics
$436.43Mn
2.50
-0.79%
+46.20%
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing IKT-001, an oral prodrug of imatinib, which is a small-molecule branded prescription drug candidate for pulmonary arterial hypertension.
PRLD
2nd
Prelude Therapeutics
$435.73Mn
5.46
+4.00%
+378.95%
The company also develops small-molecule inhibitors, such as the mutant-selective JAK2 inhibitor PRT12396, which falls under the development of branded prescription pharmaceuticals.
VTVT
vTv Therapeutics
$413.85Mn
33.35
-0.36%
+79.88%
vTv Therapeutics focuses on developing orally administered small-molecule therapies, such as the liver selective glucokinase activator cadisegliatin and a PDE4 inhibitor. These are branded prescription drug candidates targeting metabolic and inflammatory diseases like type 1 and type 2 diabetes.
IRD
2nd
Opus Genetics
$385.97Mn
4.67
+1.52%
+264.84%
The company also develops and licenses small-molecule branded pharmaceuticals, such as Phentolamine Ophthalmic Solution for presbyopia and APX3330 for diabetic retinopathy. It generates significant revenue from the licensing of Phentolamine to Viatris.
ACHV
Achieve Life Sciences
$370.12Mn
8.49
+2.17%
+196.85%
Achieve Life Sciences is a specialty pharmaceutical company developing cytisinicline, a branded prescription drug for the treatment of nicotine dependence. The company's business model is centered on the development and future commercialization of this branded pharmaceutical product.
PALI
Palisade Bio
$362.81Mn
2.09
+1.95%
+230.33%
Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a small-molecule oral phosphodiesterase-4 (PDE4) inhibitor prodrug. Its business model focuses on the discovery and development of branded prescription pharmaceuticals for inflammatory bowel disease, specifically ulcerative colitis and Crohn's disease.
NIKA
Nika Pharmaceuticals
$359.20Mn
0.41
+0.00%
-57.29%
The company develops and distributes branded prescription medicinal products, specifically Thymus Nuclear Glycoprotein for HIV treatment and products based on the Inactivated Pepsin Fraction platform. These are sold to hospitals and healthcare providers for the treatment of patients.
VNDA
Vanda Pharmaceuticals
$328.27Mn
5.43
+1.69%
+15.04%
Vanda Pharmaceuticals develops and markets branded prescription drugs such as Fanapt for schizophrenia and PONVORY for multiple sclerosis. Its revenue is generated primarily from the sale of these branded pharmaceutical products to wholesalers and specialty pharmacies.
SION
Sionna Therapeutics
$324.28Mn
7.18
+6.37%
-70.75%
Sionna Therapeutics is a clinical-stage company developing small molecule therapies, such as SION-719 and SION-451, to treat cystic fibrosis. These drug candidates are designed as branded prescription pharmaceuticals targeting the CFTR protein's nucleotide binding domain 1.
EBS
Emergent BioSolutions
$318.06Mn
6.20
-0.64%
-20.82%
The company develops, manufactures, and markets branded prescription drugs and vaccines, including NARCAN Nasal Spray, anthrax vaccines, and smallpox vaccines. Its primary revenue is derived from the sale of these commercial and medical countermeasure products to government agencies and healthcare providers.
IMRX
Immuneering
$311.84Mn
4.82
-4.37%
-10.24%
Immuneering is a clinical oncology company developing branded prescription anti-cancer medicines, specifically its lead product candidate atebimetinib, an oral MEK inhibitor. The company's core business is the discovery and development of a novel class of medicines called Deep Cyclic Inhibitors.
FULC
Fulcrum Therapeutics
$293.70Mn
3.85
+0.26%
-44.04%
Fulcrum Therapeutics is a clinical-stage company developing branded prescription small molecules, specifically its lead candidate pociredir for the treatment of sickle cell disease. The company's core business is the discovery and development of small-molecule drugs to treat genetically defined rare diseases.
TTRX
Turn Therapeutics
$291.92Mn
9.80
-2.68%
—
Turn Therapeutics is primarily focused on developing GX-03, a non-biologic topical immunomodulator for moderate-to-severe eczema and onychomycosis. This activity constitutes the company's core drug development segment and targets the branded prescription pharmaceutical market.
ZNTL
Zentalis Pharmaceuticals
$285.96Mn
3.99
-2.92%
+133.33%
Zentalis is a clinical-stage company developing azenosertib, which is described as an oral small molecule inhibitor of the WEE1 kinase. Because it is developing a branded small-molecule pharmaceutical for oncology rather than a biologic, it fits the Pharmaceuticals category.
AKBA
Akebia Therapeutics
$263.59Mn
0.97
-1.02%
-68.91%
Akebia Therapeutics develops and commercializes branded prescription drugs for kidney disease, specifically Vafseo for anemia and Auryxia for phosphorus control. Its revenue is primarily generated from the sale of these branded pharmaceuticals in the United States.
SIGA
Siga Technologies
$235.60Mn
3.29
+1.86%
-61.79%
SIGA Technologies is a commercial-stage pharmaceutical company that develops and markets TPOXX (tecovirimat), a branded prescription antiviral drug. Its revenue is derived from the sale of this branded pharmaceutical to the U.S. government (BARDA and Department of Defense) and foreign health agencies.
FTH
2nd
Faeth Therapeutics
$226.01Mn
40.05
+2.69%
+361.41%
The company's lead product candidate, PIKTOR, is described as an oral multi node inhibitor, which is a small-molecule branded prescription drug candidate for endometrial and breast cancer.
TNXP
Tonix Pharmaceuticals Holding
$220.65Mn
13.14
-1.72%
-52.56%
Tonix Pharmaceuticals is a fully-integrated company that discovers, develops, and markets branded prescription drugs. It generates revenue from the sale of FDA-approved branded products such as TONMYA for fibromyalgia and Zembrace SymTouch and Tosymra for acute migraine.
CRDL
Cardiol Therapeutics
$220.57Mn
2.20
+1.85%
+101.83%
Cardiol Therapeutics is a clinical-stage company developing small molecule drug candidates, specifically CardiolRx and CRD 38, for the treatment of inflammatory heart diseases like pericarditis and myocarditis. These are branded prescription pharmaceutical candidates targeting specific therapeutic areas.
DERM
Journey Medical
$216.10Mn
7.86
-0.51%
+13.09%
Journey Medical is a commercial-stage pharmaceutical company that sells and markets FDA-approved branded prescription drugs for dermatological conditions, such as Emrosi, Qbrexza, and Accutane. Its revenue is primarily generated from the sale of these branded pharmaceutical products.
NERV
Minerva Neurosciences
$209.22Mn
4.43
-5.54%
+91.77%
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing roluperidone, a branded prescription drug candidate for the treatment of schizophrenia. The company's business model focuses on the discovery and development of proprietary small-molecule product candidates for central nervous system diseases.
ACOG
Alpha Cognition
$207.29Mn
9.52
+3.37%
+16.67%
Alpha Cognition develops, manufactures, and markets ZUNVEYL, a branded prescription oral tablet for the treatment of mild to moderate Alzheimer's disease. Revenue is generated from the commercial sale of this branded pharmaceutical product through wholesalers and pharmacies.
SLGL
Sol-Gel Technologies
$193.69Mn
69.52
-0.83%
+197.09%
Sol-Gel develops and markets branded prescription topical treatments for dermatology, specifically Twyneo for acne vulgaris and Epsolay for rosacea. The company generates revenue from these branded products through licensing agreements, royalties, and milestone payments from partners like Mayne Pharma.
SWKH
2nd
SWK Holdings
$192.33Mn
15.90
-4.96%
-9.35%
The company has a dedicated Pharmaceutical Development segment that engages in the development, manufacturing, and licensing of pharmaceutical compounds and drug delivery systems, such as its collaboration with Aptar.
MCUJF
Medicure
$189.94Mn
1.82
+1.68%
+156.34%
Medicure develops, manufactures, and markets branded prescription cardiovascular drugs, specifically AGGRASTAT for acute coronary syndrome and ZYPITAG for hyperlipidemia. These products are sold to drug wholesalers for distribution to hospitals and pharmacies.
LENZ
LENZ Therapeutics
$187.24Mn
5.96
+2.23%
-84.82%
LENZ Therapeutics is a commercial pharmaceutical company that develops and markets VIZZ (aceclidine ophthalmic solution), a branded prescription drug for treating presbyopia. Its revenue is derived from the sale of this branded pharmaceutical product and associated international licensing and royalty agreements.
MENS
Jyong Biotech
$181.71Mn
2.39
+5.29%
-95.82%
Jyong Biotech is a biopharmaceutical company that discovers, develops, and manufactures branded prescription drugs such as Botreso® for benign prostatic hyperplasia and PCP for prostate cancer prevention. Its revenue model is based on the commercialization of these proprietary drug candidates and licensing agreements.
LONA
LeonaBio
$179.37Mn
7.56
-0.79%
+91.88%
LeonaBio is a biopharmaceutical company developing small molecule candidates, specifically lasofoxifene for metastatic breast cancer and ATH 1105 for ALS. These are branded prescription drug candidates rather than biologics, fitting the description of Pharmaceuticals.
IFRX
2nd
InflaRx
$160.49Mn
2.22
-0.45%
+28.32%
The company is developing izicopan, which is described as an orally administered small molecule inhibitor of the C5a receptor for chronic autoimmune and inflammatory conditions.
SPRB
2nd
Spruce Biosciences
$159.47Mn
57.93
+0.38%
+559.04%
The company also develops small-molecule drugs, such as tildacerfont, a CRF1 receptor antagonist for the treatment of major depressive disorder.
TNYA
2nd
Tenaya Therapeutics
$152.48Mn
0.68
-2.86%
-45.16%
In addition to its gene therapy pipeline, the company is advancing a small molecule program, TN-301, which is a selective HDAC6 inhibitor intended for heart failure and other indications.
BMEA
Biomea Fusion
$147.14Mn
2.03
+6.28%
+5.73%
Biomea Fusion is a clinical-stage company developing oral small molecule drugs, specifically icovamenib and BMF650, for diabetes and obesity. These are branded prescription drug candidates based on synthetic chemistry rather than biological science.
VANI
Vivani Medical
$133.22Mn
1.49
+7.19%
+28.45%
Vivani Medical is a clinical-stage biopharmaceutical company developing branded drug implant candidates, specifically focusing on GLP1 receptor agonists for obesity and type 2 diabetes. Its primary business model is the development and potential commercialization of these branded prescription therapies.
NTHI
Neonc Technologies Holdings
$130.44Mn
5.03
+5.01%
-30.14%
NeOnc is a biopharmaceutical company developing branded prescription drug candidates, specifically NEO100 and NEO212, for the treatment of intracranial malignancies and Parkinson's disease. Its business model focuses on the discovery and clinical development of these small-molecule compounds derived from perillyl alcohol.
AARD
Aardvark Therapeutics
$117.74Mn
5.38
-6.11%
-36.63%
Aardvark Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics, such as ARD-101 and ARD-201, for the treatment of metabolic diseases. These are branded prescription drug candidates targeting Bitter Taste Receptors (TAS2Rs) for conditions like Prader Willi syndrome and obesity.
CPIX
Cumberland Pharmaceuticals
$101.74Mn
6.79
+0.59%
+88.09%
Cumberland Pharmaceuticals focuses on the acquisition, development, and commercialization of branded prescription pharmaceuticals. It generates revenue from the sale of FDA-approved branded products such as Acetadote, Caldolor, and Vibativ.
PYPD
2nd
PolyPid
$98.12Mn
5.39
+2.28%
+58.53%
The company's lead product candidate, D-PLEX 100, utilizes the FDA-approved antibiotic doxycycline, a branded pharmaceutical agent, to prevent surgical site infections.
CGTX
Cognition Therapeutics
$97.91Mn
1.03
-1.90%
-56.54%
Cognition Therapeutics is a clinical-stage company developing zervimesine (CT1812), which is explicitly described as an orally delivered small molecule therapeutic. The company's core business is the discovery and development of branded prescription small-molecule drugs for Alzheimer's disease and dementia with Lewy bodies.
VRCA
Verrica Pharmaceuticals
$91.05Mn
5.30
-1.12%
+1.34%
Verrica Pharmaceuticals develops and markets branded prescription drugs for dermatologic diseases, specifically its lead product YCANTH for molluscum contagiosum. Revenue is generated from the sales of this branded pharmaceutical product to healthcare providers.
FBIO
2nd
Fortress Biotech
$90.61Mn
2.72
+0.37%
-4.23%
The company generates significant revenue from branded prescription pharmaceuticals through Journey Medical Corporation, which markets FDA-approved dermatology products such as Emrosi, Qbrexza, and Accutane.
RGC
Regencell Bioscience Holdings
$89.66Mn
6.89
+6.33%
-46.34%
Regencell Bioscience Holdings focuses on the research, development, and commercialization of a standardized Traditional Chinese Medicine (TCM) formula for the treatment of ADHD and ASD. The company intends to generate revenue from the sale of these branded pharmaceutical products once they receive regulatory approval.
PTHS
Pelthos Therapeutics
$89.28Mn
24.01
-2.20%
-26.10%
Pelthos Therapeutics develops and markets branded prescription drugs, specifically ZELSUVMI, XEPI, and XEGLYZE. Its primary revenue is generated from the sale of these FDA-approved branded pharmaceutical products through distribution channels.
TENX
Tenax Therapeutics
$87.74Mn
1.94
+8.99%
-67.77%
Tenax Therapeutics is a development-stage pharmaceutical company focused on branded prescription therapies for pulmonary hypertension. Its lead product candidates, levosimendan (TNX-103) and imatinib, are small-molecule drugs being developed for commercial sale to healthcare providers and patients.
MNOV
Medicinova
$79.74Mn
1.62
+0.00%
+22.73%
Medicinova is developing oral small molecule therapeutics, specifically MN 166 and MN 001, for indications such as multiple sclerosis and glioblastoma. These are branded prescription drug candidates rather than biologics, fitting the description of pharmaceutical discovery and development.
AIFC
2nd
AI Financial
$78.31Mn
0.56
-1.75%
-87.53%
The Biotechnology segment is dedicated to developing and commercializing non-opioid therapies for chronic pain, specifically mentioning drug candidates JAN101 and JAN123.
PLRX
Pliant Therapeutics
$71.83Mn
1.16
+2.65%
-32.16%
Pliant Therapeutics is developing small molecule inhibitors, such as its lead candidate PLN-101095, which is described as an oral, small molecule dual inhibitor. Since the company focuses on branded small-molecule drug discovery and development for oncology indications, it fits the Pharmaceuticals classification.
CING
Cingulate
$70.86Mn
5.10
-2.30%
+34.56%
Cingulate is a biopharmaceutical company developing branded prescription drugs for ADHD and anxiety, such as CTx-1301 (dexmethylphenidate) and CTx-2103 (buspirone). Its revenue model is based on the development and commercialization of these branded pharmaceutical products.
PMVP
PMV Pharmaceuticals
$68.96Mn
1.29
+4.03%
-10.42%
PMV Pharmaceuticals focuses on the discovery and development of small molecule therapies, such as its lead candidate rezatapopt, to treat p53-related cancers. The company's revenue model is based on the future sales of these branded prescription pharmaceuticals and potential licensing agreements.
BOLD
Boundless Bio
$64.50Mn
2.87
+0.00%
+149.57%
Boundless Bio is a clinical-stage oncology company developing small molecule drugs to inhibit targets in ecDNA biology. Its pipeline consists of ecDNA directed therapeutic candidates intended for patients with oncogene amplified cancers such as breast and gastric cancer.
VERU
Veru
$60.85Mn
2.64
-0.38%
-20.24%
Veru is a biopharmaceutical company developing branded prescription drugs, specifically enobosarm for obesity and sabizabulin for atherosclerotic cardiovascular disease. These are small-molecule oral medicines (a selective androgen receptor modulator and a microtubule disruptor) intended for branded pharmaceutical sales.
ANVS
Annovis Bio
$58.80Mn
1.38
+0.00%
-39.47%
Annovis Bio is developing buntanetap, which is described as an orally administered small molecule designed to treat Alzheimer's and Parkinson's disease. The company's focus on small-molecule drug discovery and development for branded prescription use aligns with the Pharmaceuticals industry.
GOSS
Gossamer Bio
$57.60Mn
0.18
+0.00%
-93.02%
Gossamer Bio is a biopharmaceutical company developing seralutinib, an inhaled small molecule inhibitor, for the treatment of pulmonary arterial hypertension. Its revenue model is based on collaboration agreements, such as the one with Chiesi, and potential future sales of these branded prescription drugs.
KPTI
Karyopharm Therapeutics
$51.80Mn
1.79
+1.13%
-74.72%
Karyopharm Therapeutics is a commercial-stage pharmaceutical company that develops and markets branded prescription drugs, specifically XPOVIO (selinexor), an oral small molecule inhibitor for cancer. Its primary revenue is derived from net product sales of this branded pharmaceutical in the United States.
PTN
2nd
Palatin Technologies
$49.68Mn
12.70
-2.91%
+38.04%
In addition to peptides, the company develops small-molecule agonists and antagonists for the treatment of obesity and metabolic related disorders, which falls under branded pharmaceutical development.
CLNN
Clene
$49.20Mn
3.85
-3.51%
-31.13%
Clene is a clinical-stage pharmaceutical company developing branded prescription therapeutics such as CNM-Au8 for the treatment of neurodegenerative diseases like ALS, MS, and Parkinson's. Its core business model is the discovery, development, and potential commercialization of these novel nanotechnology-based drugs.
IXHL
Incannex Healthcare
$44.33Mn
3.24
-0.31%
-82.69%
Incannex Healthcare is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies, such as IHL-42X for sleep apnea and PSX-001 for anxiety. These are described as combinations of active agents (small molecules) rather than biologics, fitting the profile of a branded pharmaceutical developer.
APRE
Aprea Therapeutics
$42.25Mn
0.79
-2.47%
-48.37%
Aprea Therapeutics focuses on the discovery and development of small molecule inhibitors, such as the WEE1 inhibitor APR-1051 and the ATR inhibitor ATRN-119. These are branded prescription drug candidates designed for oncology patients with biomarker-defined cancers.
APLM
2nd
Apollomics
$40.70Mn
28.15
+1.37%
+413.69%
The company also develops small-molecule tumor inhibitors, such as the lead candidate vebreltinib (a selective cMet inhibitor) and APL-102, which fall under branded pharmaceutical development.
KAPA
2nd
Kairos Pharma
$38.10Mn
1.83
+8.93%
+25.34%
In addition to antibodies, the company is developing small molecule drug candidates aimed at treating prostate, lung, breast, and glioblastoma cancers.
SCLX
Scilex Holding
$38.06Mn
5.41
+2.46%
-53.92%
Scilex Holding develops and markets branded prescription drugs for pain management, specifically ZTlido for postherpetic neuralgia, ELYXYB for acute migraine, and GLOPERBA for gout prophylaxis. Revenue is generated from the sales of these branded pharmaceutical products to wholesalers and healthcare providers.
ACTU
Actuate Therapeutics
$35.54Mn
1.48
+8.03%
-82.81%
Actuate Therapeutics is developing elraglusib, which is described as an ATP-competitive small molecule for the treatment of cancers. Because it is focused on small-molecule drug development rather than biologics, it fits the Pharmaceuticals category.
GRCE
Grace Therapeutics
$34.18Mn
2.10
-1.87%
-29.29%
Grace Therapeutics is a biopharmaceutical company developing branded prescription drug candidates for rare diseases such as aneurysmal subarachnoid hemorrhage and ataxia telangiectasia. Its business model focuses on the development and commercialization of these branded therapies via the 505(b)(2) regulatory pathway.
NSRX
Nasus Pharma
$33.63Mn
3.73
-0.53%
-53.44%
Nasus Pharma is a clinical-stage pharmaceutical company developing branded prescription drugs, specifically NS002 (intranasal epinephrine) and NS001 (intranasal naloxone). Its business model is based on the future sale of these proprietary, branded pharmaceutical products for emergency medical conditions.
BETRF
2nd
BetterLife Pharma
$33.42Mn
0.22
+4.76%
+214.29%
The company also develops small-molecule pharmaceutical candidates for neuropsychiatric indications, such as BETR-001 (a non-hallucinogenic LSD derivative) and BETR-002 (a formulation of dihydrohonokiol).
CPHI
China Pharma Holdings
$33.23Mn
0.82
-3.53%
-43.06%
The company develops, manufactures, and markets branded prescription pharmaceuticals such as Candesartan tablets for hypertension and Gastrodin Injection for cerebrovascular support. These products are sold through distributors to state-owned hospitals.
UG
United Guardian
$32.80Mn
7.14
+0.99%
-17.84%
The company's largest revenue stream (51%) comes from pharmaceutical products, specifically Renacidin, which is an FDA-approved drug for preventing and dissolving urethral catheter calcifications.
MDBH
2nd
MDB Capital Holdings
$30.18Mn
2.93
-2.01%
-16.29%
Through MDB Minnesota One Inc, the company is developing a small molecule anti-senescence platform consisting of pharmaceutical drugs aimed at promoting longevity and inhibiting age-related diseases.
CRVO
CervoMed
$26.23Mn
2.56
+0.79%
-76.05%
CervoMed is developing neflamapimod, which is explicitly described as an orally administered, small-molecule drug candidate. The company's primary business is the discovery and development of branded prescription pharmaceuticals for neurodegenerative diseases like dementia with Lewy bodies.
YARW
Yarrow Bioscience
$25.92Mn
30.21
+4.71%
+90.00%
VYNE Therapeutics is a biopharmaceutical company developing small molecule BET inhibitors, specifically repibresib gel (VYN201) and VYN202. These are branded prescription drug candidates targeting inflammatory and immune-mediated conditions like vitiligo and plaque psoriasis.
TXMD
TherapeuticsMD
$25.58Mn
2.21
-1.34%
+104.63%
TherapeuticsMD holds patents and trademarks for branded prescription drugs in women's healthcare, specifically hormone therapy and contraceptive solutions like IMVEXXY, BIJUVA, and ANNOVERA. Although it now operates as a royalty company, its core business is the ownership and monetization of branded pharmaceutical assets.
BYSI
BeyondSpring
$25.49Mn
0.62
+0.00%
-66.30%
BeyondSpring is a biopharmaceutical company focused on developing Plinabulin, which is described as a first-in-class small molecule microtubule modulator. Its pipeline consists of small-molecule oncology programs (BPI-002, BPI-003, BPI-004) and targeted protein degradation molecules via its interest in SEED Therapeutics.
ATOS
Atossa Therapeutics
$25.15Mn
2.52
-0.40%
-78.18%
Atossa Therapeutics is developing Z endoxifen, which is described as an oral small molecule acting as a selective estrogen receptor modulator and degrader. The company's focus is on branded prescription medicines for oncology and rare diseases, fitting the profile of a pharmaceutical developer of small-molecule drugs.
AYTU
Aytu Biopharma
$23.72Mn
2.21
-3.49%
-5.56%
Aytu Biopharma discovers, develops, and markets branded prescription drugs, specifically focusing on CNS diseases. Its primary revenue is generated from the sale of branded therapeutics such as EXXUA for major depressive disorder and Adzenys for ADHD.
BFRI
Biofrontera
$22.87Mn
1.61
+6.62%
+85.06%
Biofrontera is a pharmaceutical company that develops and markets branded prescription drugs, specifically Ameluz for the treatment of actinic keratosis. Its revenue is derived from the sale of these branded prescription dermatological products to healthcare providers and distributors.
ALLR
Allarity Therapeutics
$22.59Mn
1.42
-0.70%
-21.98%
Allarity Therapeutics is a pharmaceutical company focused on developing novel anti-cancer therapeutics, specifically its lead candidate stenoparib, a dual inhibitor of PARP1/2 and tankyrases. The company's primary business objective is the clinical development and potential commercialization of these branded prescription drugs for patients with ovarian and small cell lung cancer.
MIRA
Mira Pharmaceuticals
$18.01Mn
0.76
+2.70%
-45.32%
Mira Pharmaceuticals is a clinical-stage pharmaceutical development company focusing on branded prescription drug candidates. Its pipeline includes an oral ketamine analog for neuropathic pain and an oral pharmaceutical marijuana molecule for dementia and anxiety.
TVRD
Tvardi Therapeutics
$17.92Mn
1.91
+3.24%
-93.36%
Tvardi Therapeutics is developing oral small molecule therapies, specifically TTI-101 and TTI-109, to treat inflammatory and proliferative diseases. These are branded prescription drug candidates targeting hepatocellular carcinoma and idiopathic pulmonary fibrosis, which fits the profile of a pharmaceutical company developing small-molecule branded drugs.
CTXR
Citius Pharmaceuticals
$16.20Mn
0.59
-1.67%
-51.64%
Citius Pharmaceuticals develops and markets branded prescription drugs, specifically the FDA-approved lymphoma therapy LYMPHIR. Its revenue is derived from the sales of these branded pharmaceutical products to hospitals and oncology clinics.
RKTO
2nd
Rocket One
$16.00Mn
0.69
+0.00%
-48.51%
The company is developing several small-molecule or formulation-based branded prescription drugs, including HT-001 for skin toxicities and HT-KIT for mast cell derived cancers, which fall under traditional pharmaceutical development.
KPRX
Kiora Pharmaceuticals
$15.75Mn
2.55
+0.00%
-6.59%
Kiora Pharmaceuticals is a clinical-stage pharmaceutical company developing branded prescription therapies such as KIO 301 for retinitis pigmentosa and KIO 104 for retinal inflammatory diseases. Its business model focuses on the discovery and development of small-molecule drugs, including a photoswitch molecule and a dihydroorotate dehydrogenase inhibitor.
ANEB
Anebulo Pharmaceuticals
$14.79Mn
0.36
-7.69%
-85.37%
Anebulo Pharmaceuticals is developing selonabant, a small molecule CB1 antagonist, which is a branded prescription drug candidate. The company's business model is focused on the discovery, development, and future commercialization of this branded pharmaceutical to treat cannabis-induced toxicity.
QCLS
2nd
Q
$14.66Mn
1.79
-4.79%
-48.56%
The company maintains a pharmaceutical business developing branded prescription candidates, specifically Isomyosamine, a small molecule for autoimmune diseases, and Supera CBD for epilepsy and pain.
INTI
Inhibitor Therapeutics
$12.17Mn
0.07
+0.00%
+75.00%
Inhibitor Therapeutics is a pharmaceutical development company focused on creating and commercializing branded therapeutics for oncology and rare diseases, specifically using itraconazole for basal cell carcinoma nevus syndrome, prostate cancer, and lung cancer. Its business model relies on future branded product sales, milestone payments, and royalties.
CALC
CalciMedica
$7.42Mn
2.17
-1.36%
-32.61%
CalciMedica is developing small molecule CRAC channel inhibitors, specifically Auxora (containing zegocractin) and CM5480. These are branded prescription drug candidates targeting inflammatory and immunologic processes, which fits the profile of a pharmaceutical company.
CURX
Curanex Pharmaceuticals
$7.22Mn
5.09
+7.38%
-28.31%
Curanex Pharmaceuticals is a developmental stage company focused on discovering and commercializing botanical drugs, such as its lead candidate Phyto N, for the treatment of inflammatory diseases. Its future revenue model is based on the sale of branded prescription pharmaceuticals to healthcare providers and specialty pharmacies.
RVPH
Reviva Pharmaceuticals Holdings
$6.95Mn
0.53
-1.85%
-94.24%
Reviva Pharmaceuticals is a pharmaceutical company developing new chemical entities, such as brilaroxazine (RP5063) and RP1208, for central nervous system and cardiometabolic conditions. The company focuses on discovering and developing branded prescription drugs for psychiatric and neurologic disorders.
ACXP
Acurx Pharmaceuticals
$6.65Mn
1.42
+1.43%
-63.21%
Acurx Pharmaceuticals is developing a new class of small molecule antibiotics, such as ibezapolstat, to treat bacterial infections. Its revenue model is based on the future sale of these branded prescription pharmaceuticals or licensing them to larger pharmaceutical firms.
PCSA
Processa Pharmaceuticals
$5.75Mn
2.06
+0.49%
-56.17%
Processa Pharmaceuticals focuses on developing small molecule therapies, such as NGC Cap for breast cancer and PCS12852 for gastroparesis. These are branded prescription drug candidates rather than biologics, fitting the definition of Pharmaceuticals.
TRAW
Traws Pharma
$5.59Mn
0.55
+1.85%
-65.84%
Traws Pharma is a biopharmaceutical company developing small-molecule drug candidates such as tivoxavir marboxil (an endonuclease inhibitor) and narazaciclib (a kinase inhibitor). These are branded prescription drug candidates targeting influenza, COVID-19, and oncology, which fits the profile of a pharmaceutical developer.
PULM
Pulmatrix
$5.08Mn
1.39
+2.21%
-70.11%
Pulmatrix develops branded prescription inhaled therapeutics, such as PUR3100 for migraine and PUR1800 for COPD. These are small-molecule drug candidates designed for specific therapeutic indications, fitting the profile of a branded pharmaceutical developer.
TPST
2nd
Tempest Therapeutics
$5.07Mn
1.03
-1.90%
-90.19%
The company also advances a segment of oral small molecule inhibitors, such as amezalpat for hepatocellular carcinoma and TPST 1495 for familial adenomatous polyposis, which are branded prescription drug candidates.
INM
2nd
InMed Pharmaceuticals
$4.57Mn
1.38
+3.76%
-34.60%
InMed discovers and develops proprietary small molecule drug candidates, such as INM901 for Alzheimer's and INM089 for macular degeneration, with the intent to file new drug applications for branded prescription pharmaceuticals.
TCRT
Alaunos Therapeutics
$4.05Mn
1.63
-1.21%
-27.23%
Alaunos Therapeutics is developing orally administered small molecule therapeutics, specifically its lead candidate ALN1003, for obesity and metabolic disorders. Because it focuses on small-molecule drug discovery and development rather than biologics, it fits the Pharmaceuticals category.
CVKD
Cadrenal Therapeutics
$3.78Mn
1.22
-4.69%
-90.52%
Cadrenal Therapeutics is a biopharmaceutical company developing branded prescription drugs, including CAD 1005 for heparin induced thrombocytopenia, tecarfarin as a vitamin K antagonist, and frunexian as a Factor XIa inhibitor. These are small-molecule therapeutic candidates intended for commercial sale to hospitals and clinicians.
BICX
BioCorRx
$3.63Mn
0.21
+0.00%
-53.33%
The company develops and markets branded prescription drugs, specifically the FDA-approved medication Lucemyra for opioid withdrawal and the clinical-stage implantable naltrexone pellet BICX104. Revenue is generated from the sale and distribution of these pharmaceutical products.
ADXN
Addex Therapeutics
$3.27Mn
3.65
-1.62%
-54.88%
Addex Therapeutics is a clinical-stage pharmaceutical firm focused on the discovery and development of novel orally available small molecule drug candidates, such as dipraglurant and ADX71149. Its business model centers on developing branded prescription pharmaceuticals for indications like post-stroke traumatic brain injury recovery and chronic cough.
CASIF
CASI Pharmaceuticals
$2.88Mn
0.14
-6.67%
-94.04%
CASI Pharmaceuticals develops and commercializes branded prescription drugs for hematology, oncology, and autoimmune areas, generating revenue from products like EVOMELA and FOLOTYN. Its business model focuses on acquiring and launching innovative medicines in the China market.
OGEN
Oragenics
$2.35Mn
0.52
+4.00%
-51.40%
Oragenics is a biopharmaceutical company developing ONP 002, a synthetic neurosteroid for the treatment of mild traumatic brain injury. The company's business model focuses on the discovery and development of branded prescription pharmaceutical therapies for neurological conditions.
BTAI
2nd
BioXcel Therapeutics
$2.19Mn
0.07
-41.67%
-98.07%
The company generates revenue from the sales of IGALMI®, a branded prescription drug used for the acute treatment of agitation associated with schizophrenia or bipolar disorder.
CANF
Can-Fite BioPharma
$1.85Mn
2.25
-8.91%
-82.95%
Can-Fite BioPharma discovers and develops orally bioavailable small molecule drugs, such as Piclidenoson and Namodenoson, for the treatment of cancer, liver, and inflammatory diseases. Its revenue model is based on licensing these branded prescription drug candidates to pharmaceutical partners like Cipher Pharmaceuticals and Gebro Holding.
UPC
Universe Pharmaceuticals
$1.84Mn
4.03
-6.93%
+8.04%
The company manufactures and markets its own branded traditional Chinese medicine (TCMD) products, such as Bai Nian Dan and Hu Zhuo Ren, targeting chronic conditions and cold/flu. Revenue is primarily generated from the sale of these proprietary branded pharmaceutical formulas.
JAGX
Jaguar Health
$1.44Mn
0.60
-13.04%
-98.98%
Jaguar Health is a specialty pharmaceutical company that develops and markets branded prescription drugs, such as Mytesi for HIV-related diarrhea and Gelclair for oral mucositis. Its revenue is derived from the sale of these branded prescription products and licensing agreements.
ENSC
Ensysce Biosciences
$1.18Mn
0.46
+4.55%
-78.80%
Ensysce Biosciences is a pharmaceutical company developing branded prescription drugs for severe pain relief, specifically focusing on opioid pain products like PF614. Its business model is centered on the research, development, and future commercialization of these proprietary branded therapeutics.
MTNB
Matinas BioPharma Holdings
$1.15Mn
0.18
+0.00%
-90.11%
Matinas BioPharma is a clinical-stage company developing MAT2203, an oral formulation of amphotericin B, which is a small-molecule branded prescription drug candidate for invasive fungal infections. The company's core business is the development of branded pharmaceuticals, as evidenced by its lead product candidate and its pursuit of licensing or sale of this specific drug asset.
SKVI
Skinvisible
$1.08Mn
0.20
-53.49%
-4.76%
Skinvisible develops and patents topical prescription products and delivery systems, such as Invisicare, which it licenses to pharmaceutical companies. Its revenue model is based on upfront fees and royalties from these branded pharmaceutical assets and life cycle management for drugs coming off patent.
SPRC
SciSparc
$649.49K
5.23
-1.69%
-73.71%
SciSparc is a clinical-stage pharmaceutical company developing branded prescription drug candidates such as SCI-110 and SCI-210 for CNS disorders like Tourette syndrome and Alzheimer's disease. Its revenue model includes potential commercialization of these drugs and licensing agreements with royalty-bearing rights, such as the SCI-160 pain program outlicensed to Polyrizon.
NCEL
NewcelX
$517.00K
3.35
-0.59%
—
NewcelX is a biopharmaceutical company developing branded prescription drugs, specifically lead compounds like Quilience and Nolazol (mazindol), for the treatment of narcolepsy and ADHD. Its business model focuses on the discovery, development, and potential commercialization of new chemical entities and repurposed molecules.
GLMD
Galmed Pharmaceuticals
$456.10K
3.92
+0.00%
+203.88%
Galmed Pharmaceuticals focuses on the development of Aramchol, a synthetic conjugate (small-molecule) oral SCD1 modulator for the treatment of NASH and other liver diseases. The company's revenue model is based on licensing agreements for this branded pharmaceutical candidate, such as the agreement with Samil Pharma Co. Ltd.
CDT
CDT Equity
$397.58K
0.63
-16.00%
-99.74%
CDT Equity is a pharmaceutical development company that focuses on advancing therapeutic assets like the AZD1656 glucokinase activator and AZD5904 myeloperoxidase inhibitor. Its revenue model is based on licensing these branded pharmaceutical candidates to third parties in exchange for upfront payments, milestones, and royalties.
GCAN
Trafalgar International
$217.34K
0.23
+0.00%
-48.89%
The company is developing and commercializing cannabinoid therapeutics for neuropsychiatric disorders such as autism, schizophrenia, Parkinson’s, and Alzheimer’s disease. It is currently advancing a therapeutic into Phase 2 clinical trials to create branded prescription drug products.
ZCMD
2nd
Zhongchao
$29.58K
0.85
-3.41%
-99.64%
The company operated the Xinjiang Pharmaceutical unit, which generated revenue by selling patented drugs.
SXTC
China SXT Pharmaceuticals
$29.26K
2.23
+1.36%
-98.92%
China SXT Pharmaceutical researches, develops, manufactures, and markets branded traditional Chinese medicine products under the Suxuantang brand. Its revenue is generated from the sale of Advanced, Fine, and Regular TCMP products sold to hospitals and pharmaceutical distributors.
CMND
Clearmind Medicine
$14.74K
1.16
-31.76%
-99.72%
Clearmind Medicine is a clinical-stage pharmaceutical company developing MEAI, a non-hallucinogenic molecule intended for the treatment of alcohol use disorder and obesity. The company aims to generate revenue from the sale of these branded prescription therapeutics following regulatory approval.
BZYR
Burzynski Research Institute
$0.00
0.00
—
-100.00%
The company is engaged in the research, production, and marketing of branded prescription chemical compounds called Antineoplastons for the treatment of cancer. These are described as growth inhibiting peptides and organic acids intended for regulatory approval as branded pharmaceuticals.
ITRMF
Iterum Therapeutics
$0.00
0.00
—
-100.00%
Iterum Therapeutics is a pharmaceutical company that developed and received FDA approval for ORLYNVAH™, a branded prescription antibiotic (oral sulopenem). The company intends to generate revenue through the commercial sale of this branded pharmaceutical product for treating uncomplicated urinary tract infections.